太阳集团见好就收9728(中国)有限公司

  • Home
  • Respect Talents
    1. Office Env
    2. Promotion Space
    3. Personnel Policy
    4. Entry Notice
    5. Benefits
    6. Job Demand

    Respect Talents

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • About Us
    1. Company Profile
    2. Company History
    3. Affiliation Structure

    About Us

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • Registration Declaration
    1. Import Registration
    2. Approved Varieties
    3. Related Varieties
    4. Variety in report
    5. Species to be reported
    6. Declared varieties

    Registration Declaration

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • R & D field
    1. R&D Catalog
    2. Psychotropic Drugs
    3. Medicinal chemistry
    4. Chemical Synthesis
    5. Chemical Analysis
    6. Pharmaceutical Preparations
    7. Pharmacological Research
    8. Drug Toxicology

    R & D field

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • R&D Equipment
    1. Equipment
    2. Laboratory

    R&D Equipment

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • News
    1. Company News
    2. Industry News
    3. Latest Announcement

    News

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • External Information

    External Information

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • Contact Us

    Contact Us

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

Accurately "strike" leukemia! Chinese scientists have developed a new therapeutic leukemia vaccine

Time:2021-12-16 Views:340

As one of the malignant tumors of the hematological system, leukemia seriously threatens human health. Although conventional chemotherapy has made progress, many patients still face difficult problems, including severe toxicity and insensitivity to chemotherapy. Recently, immunotherapy has become a new breakthrough in the treatment of leukemia. Although multiple vaccinations have been carried out in many programs, the effect has not yet reached the expected level.


In response, on October 12th, researchers from the Institute of Process Engineering, Chinese Academy of Sciences and Zhujiang Hospital of Southern Medical University developed a therapeutic vaccine that can co-encapsulate epitope peptides and PD-1 antibodies in self-healing microcapsules In order to accurately treat leukemia. In the new vaccine, epitope peptides and PD-1 antibodies can be easily, gently, and efficiently loaded into polylactic acid microcapsules through the unique self-repair function of microcapsules. Related research results were published on "Nature Biomedical Engineering".


Specifically, in order to construct this vaccine, researchers used polylactic acid (a material approved by the FDA) to synthesize microspheres with a huge porous structure (giga-porous microspheres), which can effectively load mixed epitope peptides and peptides in a diffusion manner. PD-1 antibody. Because the pores on the surface of the microspheres have unique healing properties under mild conditions, epitope peptides and PD-1 antibodies can be effectively co-encapsulated as cargo in the final microcapsules.


In mouse experiments, after a single administration, the beneficial chemokines and cytokines produced at the vaccination site recruited and activated antigen-presenting cells. At the same time, the gradual degradation of the microcapsules leads to the sustained release of the two wrapped goods. Correspondingly, epitope peptides can be effectively absorbed by recruited antigen-presenting cells, while PD-1 antibodies are transported to the lymph for T cell regulation. Through the coordination of these functions, researchers have achieved substantial improvements in the activation of specific cytotoxic lymphocytes.


The researchers also verified the availability of new vaccines using various epitope peptides in different models, such as murine leukemia, humanized cell line leukemia xenografts (CDX), and patient-derived leukemia xenografts (PDX) models . In all leukemia treatment models, the microcapsule-based preparations showed better performance than ISA adjuvants (commercial adjuvants), systematically inhibiting leukemia with almost no abnormalities. With its high performance and safety, the vaccine can be used as a promising immunotherapy to treat leukemia clinically.


The researchers emphasized that based on the advantages of the FDA-approved polylactic acid material, the convenience of preparing vaccine preparations, the diversity of vaccine components, and the excellent therapeutic effect, this microcapsule-based vaccine has great potential for clinical transformation. A peer reviewer of "Nature Biomedical Engineering" described the study as a "comprehensive new platform." The reviewer also emphasized that this work is "exciting and convincing."


Next Previous

Qingdao Vayuan Pharmaceutical Technology Ltd.

TEL:0532-55678600

Fax:0532-55678586

Email:ad@vayuan.com

Time:Monday to Friday 8:30~12:00; 13:00~17:30

Address:11th Floor, No.377 Nanjing Rd. Qingdao City, Shandong Province, China

Telephone

+86-0532-55678600

Copyright © 2018-2020 Qingdao Vayuan Pharmaceutical Technology Ltd. All Rights Reserved. 备案号:鲁ICP备20020049号

XML 地图 | Sitemap 地图